KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
22/5 17:03
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals....
|
|
|
22/5 17:03
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals....